Index

Note: Page numbers of article titles are in bold type.

Abortion, 763-767,816-817,894-896 8-12 weeks, 782 12-16 weeks, 782 cervical modification, 781-783 over 16 weeks, 782, 898-901 recurrent, spontaneous, 816-817 under 8 weeks, 781-782

Actin, 757-758 Alcohol, 820-821 Amniotic fluid, 819-820 Anovulatory endometrium, 840-841 Arachidonic acid prostagtandin inhibitors,

697 see also Prostaglandin inhibitors

Arachidonic acids, see under Prostaglandins Aspirin, 697-699, 832-833,870-873

fetal growth retardation and, 875-879 hypertension and, 875-879 labour inhibition, 875 side effects of, 881-884 teratogenicity and, 882-883 see also NSAIDs

Benoxaprofen, 832-833 Blood vessels, and NSAIDs, 883

hypertension, and aspirin, 875-879

Calcium-- endometrial, 744 myometrial activity and, 757-758

Carboprost, 893-901 Cervagem, see Gemeprost Cerviprost, 797 Cervix, 771-785

collagen, 774 dilatation of, 896-898 endocrine control of, 775 functional control, 772-773

abortion, 781-783 labour induction, 777-780 prostaglandins, 775-776, 780-781

non-pregnant, 783 Collagen, cervical, 774 Congestive dysmenorrhoea, 836

Contraceptive-induced menorrhagia, 847-848 Corpus luteum, 713-714

function, 714-718 Cyclooxygenase--

and aspirin, 870-873 inhibition, 869

Daltroban, 870 Danazol, 844-846 Dazmagrel, 869 Dazoxiben, 869-870, 880 sn-l,2-Diacylglycerol (DAG), 733-735,738 Diclofenac, 832-833, 843 Diet, and prostanoid synthesis, 862-867

biochemistry, 863-865 obstetrics, 865-867 side effects, 867

Dipyridamole, 880-881 Dysmenorrhoea, 829-830,834-838

primary (spasmodic), 834-836 secondary (congestive), 836 treatment, 836-838

Ectopic pregnancy, 721-722 Eicosanoids, and pregnancy, 859-862

biochemistry, 860-861 maternal, 861-862

Eicosapentaenoic acid, see under PUFAs and also Fatty acids and Prostaglandins

Embryonic PAF, 740-741 Endocervical prostaglandin administration,

797-798 Endometriosis, 84%851

treatment of, 851 Endometrium, 731-754

anovulatory, 840-841 Ca 2+ mobilization, 744 fibrinolysis and, 842 implantation, and prostaglandins, 738-739 intracellular prostaglandin regulation, 741-

748 leukotrienes, 739-740 PAF and, 740-741

receptors, 742-744

905

906 INDEX

Endometr ium-- (cont . ) phosphatidylcholine hydrolysis, 745-748

Endothelins, 836 Ethamsylate, 846

Fallopian tubes, 720--721 Fatty acids, 859-860,865-867

dietary, 862-867 prostaglandin inhibitors, 697 prostaglandin structure, 687-697

Fetal ductus arteriosus, 883-884 Fetal growth retardation, 811,814, 875.879 Fetus, non-viable, 803.804 Fibrinolysis, 842

inhibitors, 846 Flufenamic acid, 832-833,843 Flurbiprofen, 843 Follicles, 708--709 Furegrelate, 869

Gemeprost, 781,893.901 Gestrinone, 846 Glycosaminoglycans, and the cervix, 773 G protein coupling, 744

Hypertension, pregnancy-induced, 875-879

Ibuprofen, 832-833,843 Indomethacin, 832.833,873.875

fetal ductus arteriosus, 883-884 labour inhibition, 879-880 polyhydramnios, 879 side effects of, 881.884

Inositol phosphates, as phospholipase mark- ers, 741-742

Interleukins, 819 Intrauterine fetal growth retardation, 811,

814,875-879 Isoenzymes, phospholipase C, 733 Isomerase inhibition, 86%870 IUCD, 844, 84%848

Ketoprofen, 832-833

Labour induction, 763-767, 788-804 cervical ripening, see Ripening, of cervix dysfunction, 819 inhibition, 875,879-880

by aspirin, 875 by indomethacin, 879-880

non-viable pregnancy, 803-804 preterm, 817-819 prostaglandins vs. oxytocin, 799-803 viable pregnancy, 798-803

Leukotrienes, and endometrial cell signal- ling, 739-740

see also Prostaglandins Lupus anticoagulant, see Systemic lupus

erythematosus

Medofenamic acid, 832-833, 843 Medroxyprogesterone acetate, 845-846 Mefenamic acid, 832-833,843-844 Menorrhagia, 830, 838-840

contraceptive-related, 847 management of, 842 see also Dysmenorrhoea and also Uterine

bleeding Menstrual disorders, 830,834--847 Meteneprost, 894 Mifepristone, 803-804, 894-896, 89%901

plus misoprostol, 896 Migraine, menstrual, 830 Misoprostol, 896 Myometrial contractility, 755-769

abortion and, 763-767 actin, 75%758 calcium, 758-760 induced labour, 763-767 myosin light chain kinase, 760 oxytocin, 760-761 physiology, 755-757 progesterone, 761-763

Myosin, 757-758 light chain kinase, 760

Naproxen, 832-833,843,844, 880 Neonatal vasculature, and NSAIDs, 883 Nordihydroguairetic acid, 713 Norethisterone, 845 NSAIDs, 832-833,869

side effects of, 881.884 see also Aspirin and also specific names o f

Oestrogens, cervical, 775 Oligohydramnios, 81%820 Ovarian hyperstimulation syndrome, 708,

718-720 Ovarian lipoxygenase, 711 Ovary, 708-720

follicular compartment, 708-711 hyperstimulation syndrome, see Ovarian

hyperstimulation syndrome luteal compartment, 713-714 luteal function, 715-718 ovulation, 711-713 steroids, 739 stromal compartment, 714

Ovulation, 711-713,840-841 dysfunctional bleeding, 841-842

Oxytocin, 760--761,778-780

Pelvic pain, 82%830 Peritoneal endometriosis, 84%851

TNFc~ and, 851 Phosphatidylcholine hydrolysis, endometriaL

745-748 Phosphodiesterases, 732-738

phospholipase A:, 732

INDEX 907

phospholipase C, 733-735 phospholipase D, 735-738

Phosphoinositide-specific phospholipase C, see Phospholipase C

Phospholipase A2, 732-733 Phospholipase C, 733-735

isoenzymes, 733-735 Phospholipase D, 735-738

function, 736,738 receptor regulation, 736 transphosphatidylation, 736

Phosphotipase markers, 741-742 Phospholipases, 732-738, 869

A2,732-733 C, 733-735 D, 735-738

Pimagrel, 869 Piroxicam, 832-833 Platelet activating factor (PAF), 740-741

biosynthesis, 740 embryo, 740-741 endometrium, 741

receptors, 742-744 Polyhydramnios, 819-820

indomethacin and, 879 Polyunsaturated fatty acids, see PUFAs Pre-eclampsia, 811-813 Pregnancy, 788-804,809-811

alcohol in, 820-821 diet and, 865-867 ectopic, 721-722 fetal growth retardation, 811,814, 875-879 labour, see under Labour induction second trimester, 898-901 systemic lupus erythematosus and, 814-816 tobacco and, 820.821 see also Abortion

Pre-induced labour, see Ripening, of cervix Premenstrual syndrome, 830, 848-849

treatment, 849 Preterm labour, 817-819 Primary dysmenorrhoea, 834-836 Progesterone, 761-763

cervical, 775 Progesterone contraception, 847-848 Prostacyclin, 710

pre-eclampsia, 811-813 Prostaglandin-endoperoxide synthetase, 714 Prostaglandin inhibitors, 679-699, 830-832,

843-845 side-effects, 845 synthetic pathways, 830-832

Prostaglandins-- abortion, see under Abortion alcohol and, 820.821 analogues, 893--903 biochemistry, 687-706, 859-861

and diet, 862-865 in menorrhagia, 830-832

biosynthesis, 691-699 endometrial, 732 inhibition, 697-699 mechanisms, 694-697 substrates, 691-694

cervical ripening, see Ripening, of cervix cervix and, 771-785 chemistry of, 687-706 diet and, 862-867 ectopic pregnancy, 721-722 eicosanoid biochemistry, 859-861 endocervical administration of, 797-798 endometrium and, 731-754 fallopian tubes, 720-721 fetal growth retardation, 811,814,875-879 induced abortions, see Abortion inhibitors, see Prostaglandin inhibitors intracellular endometrial synthesis, 741-

748 labour dysfunction, 819 labour induction, 763-767, 788-804

non-viable pregnancy, 803-804 viable pregnancy, 78%803

labour, preterm, 817-819 menorrhagia, 830 metabolism, 699-702

endometrial, 732 myometrial contractility, 755-769 nomenclature, 687-691 and obstetrics, 809-827; see also specific

obstetrical aspects OHSS, see Ovarian hyperstimulation

syndrome oligohydramnios, 819-820 ovary and, see under Ovary and also

Ovarian aspects vs. oxytocin, in labour induction, 799-803 pelvic pain, 829-830 peritoneal endometriosis, 849-851 polyhydramnios, 819-820 post-term pregnancy, 819 pre-eclampsia, 811-813 pregnancy, 809-811, 859-891; see also

under Pregnancy preterm labour, 817-819 recurrent spontaneous abortion, 816-817 route of administration, labour induction,

796-798 SLE, 814-816 smoking, 820-821 spontaneous abortion, 763-767

recurrent, 816-817 structure of, 687-691 therapeutic uses of, 787-808; see also

specific uses vaginal administration, 797

Protein kinase C, 709 PUFAs, 85%860

dietary, 862-867

908

P UF A s - - ( cont, ) obstetric, 865-867

Pyrazolones, 832-833

Receptors-- endometrial, 736

PAF, 742-744 thromboxane, 870,880

Relaxin, 775 Ripening, of cervix, 773-775, 777-781,789-

798 abortion and, 781-783 labour induction, 777-780 prostaglandins and, 775-776,780-78t, 789-

798 actions of, 789-796 administration, 796-798

Ritodrine, 879 RU486, see Mifepristone

Salicylic acid derivatives, 832-833 see also Aspirin and alamo NSAIDs

Secondary dysmenorrhoea, 836 Smoking, 820-821 Softening, of the cervix, see Ripening, of

cervix Spasmodic dysmenorrhoea, 834-836 Stromal prostaglandins, 714 Sulindac, 832-833 Sulotroban, 870 Sulprostone, 781,803,893-901

INDEX

Systemic lupus erythematosus, 814-816

Tamoxifen, 846 Therapeutic abortion, see Abortion Thromboxane synthase, 880 Thromboxanes, 710-711

alcohol and, 820--821 diet and, 864-865 IUGR, 814 normal pregnancy, 809-810 preterm labour, 818 receptor antagonists, 870, 880 SLE, 814-816 smoking, 820-821 spontaneous abortion, 816-817 see also under Prostaglandins

Tolfenamic acid, 832-833, 851 Tranexamic acid, 845-846 Transphosphadylation, endometrial, 736 Tumour necrosis factor, 851

Uterine bleeding, 840-847 anovulatory cycles, 840-841 causes, 840 ovulatory dysfunction, 841-842 therapy, 842-847

Uterine ischaemia, 836 Uterus, 755-769

Vaginal prostaglandin administration, 797 Vasopressin, 835-836